Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Ligand Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Ligand Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was 20.3%. For fiscal 2025 it was 46.4%, against -2.4% the year before. The highest annual figure on record is 523.2% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.4% | +48.8 |
| FY2024 | Dec 31, 2024 | -2.4% | −42.1 |
| FY2023 | Dec 31, 2023 | 39.7% | +56.7 |
| FY2022 | Dec 31, 2022 | -17.0% | −40.7 |
| FY2021 | Dec 31, 2021 | 23.7% | +25.5 |
| FY2020 | Dec 31, 2020 | -1.8% | −525.0 |
| FY2019 | Dec 31, 2019 | 523.2% | +466.2 |
| FY2018 | Dec 31, 2018 | 57.0% | +48.1 |
| FY2017 | Dec 31, 2017 | 8.9% | +10.4 |
| FY2016 | Dec 31, 2016 | -1.5% | −321.1 |
| FY2015 | Dec 31, 2015 | 319.6% | +301.0 |
| FY2014 | Dec 31, 2014 | 18.6% | −4.7 |
| FY2013 | Dec 31, 2013 | 23.3% | +25.0 |
| FY2012 | Dec 31, 2012 | -1.7% | −34.0 |
| FY2011 | Dec 31, 2011 | 32.3% | +76.4 |
| FY2010 | Dec 31, 2010 | -44.1% | −39.1 |
| FY2009 | Dec 31, 2009 | -5.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -36.2% | −137.7 |
| Q2 FY2026 | Jun 30, 2026 | 76.2% | +66.0 |
| Q1 FY2026 | Mar 31, 2026 | -25.8% | +67.8 |
| Q4 FY2025 | Dec 31, 2025 | 75.1% | +147.7 |
| Q3 FY2025 | Sep 30, 2025 | 101.6% | +115.4 |
| Q2 FY2025 | Jun 30, 2025 | 10.2% | +135.2 |
| Q1 FY2025 | Mar 31, 2025 | -93.6% | −371.7 |
| Q4 FY2024 | Dec 31, 2024 | -72.6% | −137.3 |
| Q3 FY2024 | Sep 30, 2024 | -13.8% | +17.4 |
| Q2 FY2024 | Jun 30, 2024 | -125.0% | −133.7 |
| Q1 FY2024 | Mar 31, 2024 | 278.1% | +182.7 |
| Q4 FY2023 | Dec 31, 2023 | 64.7% | +99.4 |
| Q3 FY2023 | Sep 30, 2023 | -31.3% | −31.9 |
| Q2 FY2023 | Jun 30, 2023 | 8.7% | +10.5 |
| Q1 FY2023 | Mar 31, 2023 | 95.4% | +137.5 |
| Q4 FY2022 | Dec 31, 2022 | -34.7% | −25.1 |
| Q3 FY2022 | Sep 30, 2022 | 0.7% | −22.3 |
| Q2 FY2022 | Jun 30, 2022 | -1.8% | −40.7 |
| Q1 FY2022 | Mar 31, 2022 | -42.1% | −81.0 |
| Q4 FY2021 | Dec 31, 2021 | -9.6% | −17.8 |
| Q3 FY2021 | Sep 30, 2021 | 23.0% | +39.0 |
| Q2 FY2021 | Jun 30, 2021 | 39.0% | −14.4 |
| Q1 FY2021 | Mar 31, 2021 | 38.9% | +111.6 |
| Q4 FY2020 | Dec 31, 2020 | 8.2% | +35.5 |
| Q3 FY2020 | Sep 30, 2020 | -16.0% | +45.5 |
| Q2 FY2020 | Jun 30, 2020 | 53.3% | +111.0 |
| Q1 FY2020 | Mar 31, 2020 | -72.8% | −1605.1 |
| Q4 FY2019 | Dec 31, 2019 | -27.3% | +44.0 |
| Q3 FY2019 | Sep 30, 2019 | -61.5% | −209.0 |
| Q2 FY2019 | Jun 30, 2019 | -57.7% | −139.0 |
| Q1 FY2019 | Mar 31, 2019 | 1532.4% | +1451.7 |
| Q4 FY2018 | Dec 31, 2018 | -71.3% | +0.0 |
| Q3 FY2018 | Sep 30, 2018 | 147.5% | +0.0 |
| Q2 FY2018 | Jun 30, 2018 | 81.3% | +0.0 |
| Q1 FY2018 | Mar 31, 2018 | 80.6% | +0.0 |
| Q4 FY2017 | Dec 31, 2017 | -71.3% | −63.1 |
| Q3 FY2017 | Sep 30, 2017 | 147.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 81.3% | – |
| Q1 FY2017 | Mar 31, 2017 | 80.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -8.2% | – |
See a number that looks wrong?